Fidelity Investments’s Aprea Therapeutics APRE Stock Holding History

Fidelity Investments’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$36	Buy	+45	New	+$38	﹤0.01%	5464
2025 Q3	–	Sell	-501	Closed	-$852	–	5374
2025 Q2	$852	Buy	+501	New	+$854	﹤0.01%	4980
2024 Q2	–	Sell	-161	Closed	-$1.08K	–	5355
2024 Q1	$1.08K	Buy	+161	New	+$1K	﹤0.01%	4774
2022 Q1	–	Sell	-10	Closed	-$1K	–	4921
2021 Q4	$1K	Buy	+10	New	+$883	﹤0.01%	4086
2021 Q1	–	Sell	-63,064	Closed	-$6.21M	–	3952
2020 Q4	$6.21M	Sell	63,064 -94,933	-60%	-$45.1M	﹤0.01%	2121
2020 Q3	$76M	Buy	157,997 +87	+0.1%	+$48.7K	0.01%	1046
2020 Q2	$122M	Buy	157,910 +6,587	+4%	+$4.32M	0.01%	803
2020 Q1	$105M	Buy	151,323 +44,202	+41%	+$32.4M	0.01%	735
2019 Q4	$98.3M	Buy	+107,121	New	+$59M	0.01%	917

Other funds holding APRE

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Fidelity Investments's APRE Position: Q2 2026 in Review

Fidelity Investments opened a new position in Aprea Therapeutics (APRE) in Q2 2026: 45 shares worth $36. The stake represents ﹤0.01% of the portfolio and ranks #5464 among its holdings. This is a return to the name: Fidelity Investments previously reported a position in APRE as recently as Q2 2025.

Fidelity Investments first reported a position in APRE in Q4 2019 and has held it in 9 quarters since. The position peaked at $122M in Q2 2020. 27 funds tracked by Wall St. Rank hold APRE as of Q2 2026.

Fidelity Investments held 45 shares of Aprea Therapeutics worth $36 as of Q2 2026.
Aprea Therapeutics was a new Fidelity Investments position in Q2 2026.
Aprea Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #5464 holding.
Fidelity Investments first reported a position in Aprea Therapeutics in Q4 2019 and has held it in 9 quarters since.
Fidelity Investments's Aprea Therapeutics position peaked at $122M in Q2 2020.
27 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.